LDL subfractions in patients with myocardial infarction: effect of smoking and beta-blocker treatment

• Published in: Annals of clinical biochemistry Vol. 37 ( Pt 3); p. 313
• Main Authors: Theodoraki, T G, Tsoukatos, D C, Karabina, S A, Rallidis, L S, Papageorgakis, N H, Tselepsis, A D
• Format: Journal Article
• Language: English
• Published: England 01-05-2000
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Humans; Lipoproteins, LDL - blood; Lipoproteins, LDL - classification; Male; Middle Aged; Myocardial Infarction - blood; Myocardial Infarction - drug therapy; Smoking - adverse effects
• DOI: 10.1258/0004563001899456
• ISSN: 0004-5632

The aim of the present case-control study was to estimate, by density gradient ultracentrifugation, LDL heterogeneity in myocardial infarction, and to evaluate the effect of smoking and beta-blocker treatment on LDL subfraction profile. Our results show that patients who survive myocardial infarction have an abundance of small, dense LDL in their plasma, compared with controls. Patients who were on beta-blockers and those who smoked showed a more atherogenic LDL subfraction profile than the rest. In patients on beta-blocker treatment, the proportion of LDL3 was positively correlated with triglyceride concentration and body mass index. Dense LDL predominates in patients irrespective of smoking or beta-blocker treatment. The relative risk, calculated by logistic regression as the odds ratio of high LDL3, was 7.5 (95% confidence interval 2.5-22.1) and was not significantly influenced when smoking, beta-blocker treatment, triglycerides or the other parameters of the study were included in the statistical model.